UNSPSC 51171977: Pancrelipase

This classification denotes an adverse event associated with metabolic and laboratory abnormalities with the molecular formula C5850H8902N1606O1739S49, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FQ3DRG0N5K, more generally known as pancrelipase. European Medicines Agency schedules pancrelipase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14362MIG. The term PANCRELIPASE is an International Non-Proprietary Name or INN.

As of Q4 2014, PANCRELIPASE remains the US FDA Preferred Term for this commodity.

UNSPSC 51171977 Pancrelipase, a Commodity code, nominally identifies a specific pancreatic enzyme replacement therapy; however, recent state and local solicitations tagged with this code show no activity directly purchasing pancrelipase or related pharmaceutical products. The three recent opportunities posted under or tagged to this code span offender drug testing services (Collin County Community Supervision and Corrections Department, RFP), a state pharmacy benefit manager direct-contracting initiative (Texas HHS Commission, RFI), and a multistate cooperative purchasing agreement for generic and OTC pharmaceuticals (Minnesota Multistate Cooperative Purchasing Alliance, RFP). None of these solicitations name pancrelipase or pancreatic enzyme products as line items or scope elements. The mismatch suggests either that state and local agencies are not currently procuring pancrelipase through this code, or that the code has been misapplied to broader pharmaceutical and laboratory-services opportunities.

The geographic spread of recent activity is limited to Texas (Collin County RFP and HHS RFI) and Minnesota (MMCAP RFP, serving multiple states including Oregon). Without concrete recent solicitations for pancrelipase itself, there is no actionable pipeline to characterize. Vendors evaluating this code should confirm directly with state procurement offices whether pancrelipase procurement occurs under a different UNSPSC code or is consolidated under umbrella pharmaceutical agreements before committing business development resources.